Closing the HIV Diagnosis Gap in Germany with Gilead Sciences

Rhea-AI Summary

Gilead Sciences is partnering with local German organizations to close the HIV diagnosis gap, particularly in rural and migrant communities. Germany has achieved 90% diagnosis and treatment rates for people living with HIV, but aims to reach the UNAIDS goal of 95% by 2025. Gilead's HIVISION100 initiative brings together 45 HIV experts to share best practices and improve testing accessibility.

One key partner, AIDS-Hilfe Krefeld, utilizes a mobile clinic to offer HIV and STI testing in resource- areas. Anja Wiese, an educator for the organization, believes that collaborative efforts can help Germany achieve 100% diagnosis rates. Gilead's innovations have transformed HIV from a fatal disease to a chronic and preventable condition for many, and the company is now focused on helping end the HIV epidemic globally.

Positive

• Gilead Sciences is actively partnering with local organizations to improve HIV diagnosis rates in Germany
• The company launched the HIVISION100 initiative to help Germany reach the 95% HIV diagnosis goal set by UNAIDS for 2025
• Gilead's innovations have helped transform HIV from a fatal disease to a chronic and preventable condition for many

Negative

• None.

News Market Reaction

+2.15%

1 alert

+2.15% News Effect

On the day this news was published, GILD gained 2.15%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

NORTHAMPTON, MA / ACCESSWIRE / August 8, 2024 / Gilead Sciences

As a nation where 90% of all people living with HIV know their diagnosis and are being treated, Germany has made great strides to advance its HIV care goals. Yet the country acknowledges it still has significant work to do to close the gaps in diagnosis that still exist, mainly in its rural and migrant communities.

Early diagnosis is essential to help end the HIV epidemic, which is why Gilead partners with numerous local German organizations. Among them is AIDS-Hilfe Krefeld, whose outreach efforts include utilizing a mobile clinic to test people in resource-limited areas where there are remaining needs and gaps in care.

"We travel to rural areas and offer local HIV and STI testing to people who can't find their way to us, and we try to help people get treatment," says Anja Wiese, an educator for AIDS-Hilfe Krefeld.

Working Together Towards 100% Diagnosis
Gilead's innovations have helped transform HIV from a fatal disease to a chronic and preventable disease for many, and it now has its sights set on helping to end the HIV epidemic. In order to help Germany achieve the 95% HIV diagnosis goal set by UNAIDS for 2025, the company recently launched the HIVISION100 initiative. To inform the initiative, 45 HIV experts, including ones from community organizations, came together to share best practices and find ways to make it easier for people to get tested.

HIV leaders like Anja believe Germany and other countries around the world can help close the gap if organizations pull together to utilize the strategies unveiled in the initiative. "I think that we can definitely achieve 95%, or even 100%," she declares.

Watch the video above to learn about the ongoing efforts underway in Germany to close the diagnosis gap.

Originally published by Gilead Sciences

View additional multimedia and more ESG storytelling from Gilead Sciences on 3blmedia.com.

Contact Info:
Spokesperson: Gilead Sciences
Website: https://www.3blmedia.com/profiles/gilead-sciences
Email: info@3blmedia.com

SOURCE: Gilead Sciences

View the original press release on accesswire.com

FAQ

What is Gilead Sciences' HIVISION100 initiative in Germany?

HIVISION100 is an initiative launched by Gilead Sciences to help Germany achieve the UNAIDS goal of 95% HIV diagnosis by 2025. It brings together 45 HIV experts to share best practices and improve testing accessibility.

How is Gilead Sciences (GILD) addressing HIV diagnosis gaps in rural German communities?

Gilead Sciences partners with local organizations like AIDS-Hilfe Krefeld, which uses mobile clinics to offer HIV and STI testing in resource- rural areas where there are gaps in care.

What is the current HIV diagnosis rate in Germany as of 2024?

As of 2024, Germany has achieved a 90% diagnosis and treatment rate for people living with HIV, but aims to reach the UNAIDS goal of 95% by 2025.

How has Gilead Sciences (GILD) contributed to HIV treatment advancements?

Gilead's innovations have helped transform HIV from a fatal disease to a chronic and preventable condition for many patients. The company is now focused on helping to end the HIV epidemic globally.